AlphaTON Capital (ATON) Registration Filing summary

Company overview and business model

• Operates two primary businesses: digital asset investment (focused on TON token) and immune-oncology R&D.

• Allocates 99% of net cash from recent private placement to TON token acquisition, with 1% for operations and $4M for oncology.

• Seeks to capitalize on TON's integration with Telegram, targeting exposure to blockchain asset appreciation.

• Immune-oncology business focuses on developing therapies targeting checkpoint resistance in invasive cancers.

• Exploring strategic alternatives for the oncology segment, including partnerships, asset sales, or restructurings.

Financial performance and metrics

• Raised approximately $36.2M in gross proceeds via private placement in September 2025.

• Acquired an initial $30M tranche of TON and USD1 from the private placement.

• As of December 2, 2025, 8,187,488 ordinary shares outstanding; over 10% issued in exchange for cryptocurrency.

• Auditors have included a going concern explanatory paragraph in recent financial statements.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate purposes, including working capital, acquisitions, and investments.

• Ongoing capital-raising efforts (PIPE, ATM, public offerings) to support further TON accumulation.

• $4M from private placement allocated to immune-oncology business; remainder to TON token purchases.